婴儿亚历山大病对阿莫西西林和佩拉潘内尔的反应
Susana Boronat1, Eulalia Turon-Viñas1, Noel Mac Manus1
1Pediatric Neurology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, UAB, Barcelona, Spain.
Epilepsia open
|November 6, 2024
概括
本案例研究探讨了I型亚历山大病 (AxD) 的潜在治疗方法,这是一种罕见的神经退行性疾病. 阿莫西西林和帕拉曼奈尔在治疗婴儿易怒和发作方面表现有前途,为这种严重疾病提供了症状缓解.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 儿科神经学 儿科神经学
背景情况:
- 一类亚历山大病 (AxD) 是一种罕见的,严重的儿科神经退行性疾病,其特点是耐火性和脑病变,预后不好,没有确定的治疗方法.
- 这种情况是由质纤维酸蛋白 (GFAP) 基因的突变引起的,导致涉及GFAP的致病机制.
- 目前的管理重点是缓解症状,新型治疗干预措施的成功报告有限.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
255
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
255


